Clincosm LogoSign in Get a demo

Esophageal Squamous Cell Carcinoma

Showing 26 - 50 of 216
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Esophageal Squamous Cell Carcinoma Trial in Anyang, Zhengzhou (AK104, nab-paclitaxel, carboplatin)

Not yet recruiting
  • Esophageal Squamous Cell Carcinoma
  • AK104, nab-paclitaxel, carboplatin
  • Anyang, Henan, China
  • +1 more
Jun 1, 2023

Esophageal Squamous Cell Carcinoma Trial in Chongqing (Tislelizumab)

Not yet recruiting
  • Esophageal Squamous Cell Carcinoma
  • Chongqing, Chongqing, China
    Army Medical Center of the People's Liberation Army
May 26, 2023

Esophageal Squamous Cell Carcinoma, Chemoradiotherapy, Immunonutrition Trial in Hefei (Whole-course Immunonutrition Combined

Not yet recruiting
  • Esophageal Squamous Cell Carcinoma
  • +3 more
  • Whole-course Immunonutrition Combined With Chemoradiotherapy±ICIs
  • Hefei, China
    Anhui provincial hospital
Apr 16, 2023

Esophageal Squamous Cell Carcinoma, Chemo Effect, Side Effect of Drug Trial in Nanjing (Consolidation chemo (4 courses),

Recruiting
  • Esophageal Squamous Cell Carcinoma
  • +2 more
  • Consolidation chemotherapy (4 courses)
  • Concurrent chemotherapy (2 courses)
  • Nanjing, Jiangsu, China
    The First Affiliated Hospital of Nanjing Medical University
Mar 16, 2023

Esophageal Squamous Cell Carcinoma, Neoadjuvant Chemoimmunotherapy Trial (neoadjuvant anti-PD-1 (Keytruda) plus chemo)

Not yet recruiting
  • Esophageal Squamous Cell Carcinoma
  • Neoadjuvant Chemoimmunotherapy
  • neoadjuvant anti-PD-1 (Keytruda) plus chemotherapy
  • (no location specified)
Feb 14, 2023

Esophageal Cancer, Head and Neck Squamous Cell Carcinoma, Advanced Head and Neck Squamous Cell Carcinoma Trial (LSTA1,

Not yet recruiting
  • Esophageal Cancer
  • +9 more
  • (no location specified)
Feb 2, 2023

Esophageal Squamous Cell Carcinoma Trial (Paclitaxel, Irinotecan, Pembrolizumab)

Recruiting
  • Esophageal Squamous Cell Carcinoma
  • Chuo-ku, Tokyo, Japan
    National Cancer Center Hospital ( Site 3700)
Jan 31, 2023

Esophagus Cancer, Esophageal Cancer, Esophageal Tumors Trial in Pittsburgh (ActivSight)

Not yet recruiting
  • Esophagus Cancer
  • +9 more
  • ActivSight
  • Pittsburgh, Pennsylvania
    University of Pittsburgh Medical Center - Dept of Cardiothoracic
Jan 31, 2023

Esophageal Squamous Cell Carcinoma Trial in Worldwide (Durvalumab, Placebo, cisplatin + fluorouracil)

Recruiting
  • Esophageal Squamous Cell Carcinoma
  • Tucson, Arizona
  • +165 more
Jan 18, 2023

Esophageal Squamous Cell Carcinoma Trial in Worldwide (Tiragolumab, Atezolizumab, Tiragolumab Matching Placebo)

Recruiting
  • Esophageal Squamous Cell Carcinoma
  • Corona, California
  • +230 more
Jan 13, 2023

Esophageal Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Gastroesophageal Junction Carcinoma Trial in United States

Not yet recruiting
  • Esophageal Adenocarcinoma
  • +2 more
  • Palo Alto, California
  • +5 more
Jan 12, 2023

Esophageal Squamous Cell Carcinoma in Malawi

Completed
  • Esophageal Squamous Cell Carcinoma
    • Lilongwe, Malawi
    • +1 more
    Jan 5, 2023

    Esophageal Squamous Cell Carcinoma Trial in Xi'an (Tislelizumab + cisplatin + paclitaxel, Tislelizumab + radiotherapy)

    Enrolling by invitation
    • Esophageal Squamous Cell Carcinoma
    • Tislelizumab + cisplatin + paclitaxel
    • Tislelizumab + radiotherapy
    • Xi'an, Shaanxi, China
      The First Affiliated Hospital of Xi'an Jiaotong University
    Dec 21, 2022

    Small Cell Lung Cancer, NSCLC, Squamous, NSCLC, Non-squamous Trial in Worldwide (ladiratuzumab vedotin)

    Recruiting
    • Small Cell Lung Cancer
    • +8 more
    • Chandler, Arizona
    • +65 more
    Dec 19, 2022

    Esophageal Squamous Cell Carcinoma, Neoadjuvant Therapy Trial in Hangzhou (Serplulimab, Albumin paclitaxel, carboplatin AUC=5,

    Recruiting
    • Esophageal Squamous Cell Carcinoma
    • Neoadjuvant Therapy
    • Serplulimab, Albumin paclitaxel, carboplatin AUC=5, neoadjuvant therapy
    • Esophagectomy
    • Hangzhou, China
      2nd Affiliated Hospital, School of Medicine, Zhejiang University
    Dec 20, 2022

    Esophageal Squamous Cell Carcinoma, Oligometastatic Disease Trial in Guangzhou (PD-1 combined with SBRT)

    Recruiting
    • Esophageal Squamous Cell Carcinoma
    • Oligometastatic Disease
    • PD-1 combined with SBRT
    • Guangzhou, Guangdong, China
      Mian Xi
    Dec 18, 2022

    Esophageal Squamous Cell Carcinoma Trial in Shanghai (Chemotherapy (nab-paclitaxel AUC=2 and carboplatin 80mg/m2),Immunotherapy

    Not yet recruiting
    • Esophageal Squamous Cell Carcinoma
    • Chemotherapy (nab-paclitaxel AUC=2 and carboplatin 80mg/m2)，Immunotherapy (camrelizumab 200mg)、Radiotherapy(primary lesion and adjacent lymph nodes 41.4Gy， distant lymph node 0.5Gy*4)
    • Shanghai, Shanghai, China
      Shanghai Chest Hospital
    Dec 6, 2022

    Esophageal Squamous Cell Carcinoma Trial in Beijing (Fruquintinib in Combination with S-1)

    Recruiting
    • Esophageal Squamous Cell Carcinoma
    • Fruquintinib in Combination with S-1
    • Beijing, China
      Peking Union Medical College Hospital
    Dec 2, 2022

    Peripheral Blood Neoantigen Specific T Cells Predict Efficacy of

    Recruiting
    • Esophageal Squamous Cell Carcinoma
      • Shanghai, Shanghai, China
        Cancer hospital Fudan University
      Nov 30, 2022

      Advanced Solid Tumor, MSI-H/dMMR Tumors, Cutaneous Squamous Cell Carcinoma Trial in Worldwide (INCB099280)

      Recruiting
      • Advanced Solid Tumor
      • +11 more
      • Boston, Massachusetts
      • +30 more
      Dec 1, 2022

      Esophageal Squamous Cell Carcinoma, Patient-reported Outcomes, Immunotherapy Trial in Guangzhou (drug, radiation, procedure)

      Recruiting
      • Esophageal Squamous Cell Carcinoma
      • +2 more
      • Guangzhou, Guangdong, China
        Guangdong Provincial People's Hospital
      Nov 24, 2022

      Esophageal Squamous Cell Carcinoma Trial in Beijing (Pembrolizumab, Sinoporphyrin Sodium, Photodynamic therapy)

      Not yet recruiting
      • Esophageal Squamous Cell Carcinoma
      • Beijing, Beijing, China
        Beijing Cancer Hospital & Institute
      Nov 23, 2022

      Esophageal Squamous Cell Carcinoma, Esophagectomy, Radiotherapy Trial (Since the data were collected retrospectively, there were

      Completed
      • Esophageal Squamous Cell Carcinoma
      • +3 more
      • Since the data were collected retrospectively, there were no interventions
      • (no location specified)
      Oct 31, 2022

      Identification of Breath Biomarkers in Esophageal Cancer

      Recruiting
      • Esophageal Squamous Cell Carcinoma
      • Breathing test
      • Guangzhou, Guangdong, China
        Mian Xi
      Oct 27, 2022

      Esophageal Squamous Cell Carcinoma Trial in Guangzhou (Toripalimab, Paclitaxel-albumin, Nedaplatin)

      Recruiting
      • Esophageal Squamous Cell Carcinoma
      • Guangzhou, Guangdong, China
        Sun yat-sen University Cancer Center
      Oct 25, 2022